Direct-acting antiviral agents for hepatitis C: Structural and mechanistic insights

Nature Reviews Gastroenterology and Hepatology

Volumn 13, Issue 6, 2016, Pages 338-351

  Götte, Matthias ^a   Feld, Jordan J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPACIVIRIN INHIBITOR; INTERFERON; NON NUCLEOTIDE INHIBITOR; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; NONSTRUCTURAL PROTEIN 5B INHIBITOR; NUCLEOTIDE INHIBITOR; PALM SITE INHIBITOR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; THUMB SITE I INHIBITOR; THUMB SITE II INHIBITOR; UNCLASSIFIED DRUG; NS-5 PROTEIN, HEPATITIS C VIRUS; NUCLEOTIDE; VIRAL PROTEIN;

CLINICAL EFFECTIVENESS; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; VIRUS IDENTIFICATION; VIRUS INHIBITION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PHYSIOLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; NUCLEOTIDES; PROTEASE INHIBITORS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84965081537     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2016.60     Document Type: Review

References (111)

1. Mohd Hanafiah, K., Groeger, J., Flaxman, A. D. & Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57, 1333-1342 (2013).
2. Bialek, S. R. & Terrault, N. A. The changing epidemiology and natural history of hepatitis C virus infection. Clin. Liver Dis. 10, 697-715 (2006).
3. Rupp, D. & Bartenschlager, R. Targets for antiviral therapy of hepatitis C. Semin. Liver Dis. 34, 9-21 (2014).
4. Hézode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J. Hepatol. 59, 434-441 (2013).
5. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483-1493 (2014).
6. Feld, J. J. et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 370, 1594-1603 (2014).
7. Bartenschlager, R., Lohmann, V. & Penin, F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11, 482-496 (2013).
8. Lange, C. M., Jacobson, I. M., Rice, C. M. & Zeuzem, S. Emerging therapies for the treatment of hepatitis C. EMBO Mol. Med. 6, 4-15 (2014).
9. Scheel, T. K. & Rice, C. M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19, 837-849 (2013).
10. Lohmann, V. et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113 (1999).
11. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
12. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
13. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791-796 (2005).
14. Love, R. A. et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87, 331-342 (1996).
15. Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W. & Weber, P. C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7, 1353-1363 (1999).
16. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189 (2003).
17. Schiering, N. et al. A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc. Natl Acad. Sci. USA 108, 21052-21056 (2011).
18. Kwong, A. D., Kauffman, R. S., Hurter, P. & Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 29, 993-1003 (2011).
19. Hazuda, D. J., Burroughs, M., Howe, A. Y., Wahl, J. & Venkatraman, S. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. Ann. NY Acad. Sci. 1291, 69-76 (2013).
20. Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).
21. Romano, K. P., Ali, A., Royer, W. E. & Schiffer, C. A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA 107, 20986-20991 (2010).
22. Romano, K. P. et al. Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. J. Virol. 85, 6106-6116 (2011).
23. Pawlotsky, J. M. Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014. Gastroenterology 148, 468-479 (2015).
24. Summa, V. et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56, 4161-4167 (2012).
25. Liang, Y. et al. Antiviral suppression versus restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 135, 1710-1718.e2 (2008).
26. Sofia, M. J., Chang, W., Furman, P. A., Mosley, R. T. & Ross, B. S. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J. Med. Chem. 55, 2481-2531 (2012).
27. Lesburg, C. A. et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6, 937-943 (1999).
28. Bressanelli, S. et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13039 (1999).
29. Biswal, B. K. et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005).
30. Appleby, T. C. et al. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 347, 771-775 (2015).
31. Di Marco, S. et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J. Biol. Chem. 280, 29765-29770 (2005).
32. Rigat, K. L. et al. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase. J. Biol. Chem. 289, 33456-33468 (2014).
33. Kukolj, G. et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J. Biol. Chem. 280, 39260-39267 (2005).
34. Biswal, B. K. et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J. Mol. Biol. 361, 33-45 (2006).
35. Dvory-Sobol, H. et al. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 58, 6599-6606 (2014).
36. Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob. Agents Chemother. 59, 1505-1511 (2015).
37. Dutartre, H., Bussetta, C., Boretto, J. & Canard, B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2?-modified nucleotide analogues. Antimicrob. Agents Chemother. 50, 4161-4169 (2006).
38. Svarovskaia, E. S. et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin. Infect. Dis. 59, 1666-1674 (2014).
39. Tong, X. et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 209, 668-675 (2014).
40. Nguyen, L. T. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals. Antivir. Ther. http://dx.doi.org/10.3851/IMP3025 (2016).
41. Donaldson, E. F., Harrington, P. R., O'Rear, J. J. & Naeger, L. K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61, 56-65 (2015).
42. Ross-Thriepland, D. & Harris, M. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on! J. Gen. Virol. 96, 727-738 (2015).
43. Tellinghuisen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374-379 (2005).
44. Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83, 4395-4403 (2009).
45. Lambert, S. M. et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 23, 723-734 (2014).
46. Verdegem, D. et al. Domain 3 of NS5A protein from the hepatitis C virus has intrinsic α-helical propensity and is a substrate of cyclophilin A. J. Biol. Chem. 286, 20441-20454 (2011).
47. Hanoulle, X., Badillo, A., Verdegem, D., Penin, F. & Lippens, G. The domain 2 of the HCV NS5A protein is intrinsically unstructured. Protein Pept. Lett. 17, 1012-1018 (2010).
48. Belema, M. & Meanwell, N. A. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J. Med. Chem. 57, 5057-5071 (2014).
49. Feld, J. J. Interferon-free strategies with a nucleoside/nucleotide analogue. Semin. Liver Dis. 34, 37-46 (2014).
50. Barakat, K. H. et al. A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J. Chem. Inf. Model. 55, 362-373 (2015).
51. Berger, C. et al. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication. Gastroenterology 147, 1094-1105.e25 (2014).
52. Nettles, J. H. et al. Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition. J. Med. Chem. 57, 10031-10043 (2014).
53. Ascher, D. B. et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci. Rep. 4, 4765 (2014).
54. Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
55. Hézode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).
56. Feld, J. J. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology 142, 1356-1359 (2012).
57. Jacobson, I. M. et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J. Viral Hepat. 19 (Suppl. 2), 1-26 (2012).
58. Zeuzem, S. et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 146, 430-441.e6 (2014).
59. Dierynck, I. et al. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study. J. Infect. Dis. 210, 1871-1880 (2014).
60. Nguyen, L. T. et al. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals. Antivir. Ther. 20, 865-869 (2014).
61. Manns, M. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384, 414-426 (2014).
62. Jacobson, I. M. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384, 403-413 (2014).
63. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224 (2012).
64. Chayama, K. et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55, 742-748 (2012).
65. Ribeiro, R. M. et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 8, e1002881 (2012).
66. Powdrill, M. H. et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl Acad. Sci. USA 108, 20509-20513 (2011).
67. Chayama, K. & Hayes, C. N. HCV drug resistance challenges in Japan: the role of pre-existing variants and emerging resistant strains in direct acting antiviral therapy. Viruses 7, 5328-5342 (2015).
68. Lawitz, E. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384, 1756-1765 (2014).
69. Kwo, P. et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: optimist-1 [abstract LP14]. J. Hepatol. 62, S270 (2015).
70. Lawitz, E. et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: optimist-2 [abstract LP04]. J. Hepatol. 62, S264-S265 (2015).
71. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932-954 (2015).
72. Poordad, F. et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 313, 1728-1735 (2015).
73. Lawitz, E. et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in ≥95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial [oral presentation]. Hepatology 58, 86A (2013).
74. Gentile, I. et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr. Med. Chem. 21, 3261-3270 (2014).
75. Ferenci, P. et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 370, 1983-1992 (2014).
76. Feld, J. J. et al. TURQUOISE-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis [poster presentation P226]. J. Viral Hepat. 22 (Suppl. 2), 134-135 (2015).
77. Poordad, F. et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973-1982 (2014).
78. Pol, S. et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results [abstract 1928]. Hepatology 60 (Suppl. 1), 1128A (2014).
79. Forns, X. et al. C-SALVAGE: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic HCV-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy [abstract O001]. J. Hepatol. 62, S190 (2015).
80. Zeuzem, S. et al. The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection [abstract G07]. J. Hepatol. 62, S213 (2015).
81. Krishnan, P. et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir-and dasabuvir-based regimens [abstract O057]. J. Hepatol. 62, S220 (2015).
82. Kohli, A. et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385, 1107-1113 (2015).
83. McKenzie, R. et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333, 1099-1105 (1995).
84. Dyson, J. K. et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J. Hepatol. 64, 234-238 (2016).
85. Welker, M. W. et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J. Hepatol. 64, 790-799 (2016).
86. Renet, S. et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 149, 1378-1380.e1 (2015).
87. Lawitz, E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878-1887 (2013).
88. Jacobson, I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867-1877 (2013).
89. Gane, E. J. et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
90. Zeuzem, S. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370, 1993-2001 (2014).
91. Lawitz, E. et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383, 515-523 (2014).
92. Foster, G. R. et al. Sofosbuvir + peginterferon/ribavirin for 12 weeks versus sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the Boson Study [abstract LO5]. J. Hepatol. 62, S259-S260 (2015).
93. Sulkowski, M. S. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370, 211-221 (2014).
94. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889-1898 (2014).
95. Kowdley, K. V. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370, 1879-1888 (2014).
96. Brown, R. S. et al. Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes [abstract LP39]. J. Hepatol. 62, S283 (2015).
97. O'Brien, T. R., Feld, J. J., Kottilil, S. & Pfeiffer, R. M. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6, 000, 000 IU/mL. Hepatology 63, 28-30 (2016).
98. Bourliere, M. et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect. Dis. 15, 397-404 (2015).
99. Charlton, M. et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149, 649-659 (2015).
100. Gane, E. J. et al. Safety and efficacy of short-duration treatment with GS-9857 combined with sofosbuvir/GS-5816 in treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis [abstract LP03]. J. Hepatol. 62, S264 (2015).
101. Poordad, F. et al. C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naïve patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks [abstract O006]. J. Hepatol. 62, S192-S193 (2015).
102. Lawitz, E. et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks [abstract O005]. J. Hepatol. 62, S192 (2015).
103. Manns, M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384, 1597-1605 (2014).
104. Sarrazin, C. et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir ± RBV [abstract P0773]. J. Hepatol. 62, S620 (2015).
105. Feld, J. J. et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 373, 2599-2607 (2015).
106. Foster, G. R. et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 373, 2608-2617 (2015).
107. Li, Q. et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl Acad. Sci. USA 106, 16410-16415 (2009).
108. Baugh, J. M., Garcia-Rivera, J. A. & Gallay, P. A. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res. 100, 555-561 (2013).
109. He, S. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med. 7, 282ra49 (2015).
110. Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386, 1537-1545 (2015).
111. Dore, G. J. & Feld, J. J. Hepatitis C virus therapeutic development: in pursuit of 'perfectovir'. Clin. Infect. Dis. 60, 1829-1836 (2015).